Commentary

Video

Dr. Zhen on Future Research Efforts in Neuroendocrine Carcinomas

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

David Zhen, MD, physician, Fred Hutchinson Cancer Center, assistant professor, the University of Washington School of Medicine, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

The randomized phase 2/3 SWOG S2012 trial (NCT05058651) is evaluating the addition of atezolizumab (Tecentriq) to the standard-of-care chemotherapy for patients with metastatic small cell neuroendocrine carcinomas that originate outside the lung.

Though neuroendocrine tumors tend to be less aggressive, with patients achieving survival measured in years, poorly differentiated neuroendocrine carcinomas represent a subset of these cancers, Zhen says. These rare tumors are typically much more aggressive than other neuroendocrine tumors, Zhen explains.

Under the current standard of care, with neuroendocrine carcinomas could survive for 1 year or less, and there is a need develop improved therapies for this subset of patients, Zhen concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity